JAMA Ophthalmology

Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting

Retrieved on: 
Monday, November 6, 2023
Atrophy, Adolescence, Ageing, JAMA Ophthalmology, Principal investigator, Therapy, Natural history, Stargardt disease, Westmead, AAO, HIV disease progression rates, Baseline, Retrospective, DRAGON, Annual general meeting, University, Paratriathlon, Patient, Retina, FAF, Grade, SAN, Pharmaceutical industry, Silviculture, Ophthalmology

“Tinlarebant’s final Phase 2 results represent a significant milestone for Belite Bio and provide additional foundational support for the work being conducted across our trials,” said Dr. Tom Lin, Chairman and CEO of Belite Bio.

Key Points: 
  • “Tinlarebant’s final Phase 2 results represent a significant milestone for Belite Bio and provide additional foundational support for the work being conducted across our trials,” said Dr. Tom Lin, Chairman and CEO of Belite Bio.
  • “We are very encouraged by the promising 24-month treatment final results from this Phase 2 study.
  • The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Studies: Design and Baseline Characteristics: ProgStar Report No.
  • Progression of Stargardt Disease as Determined by Fundus Autofluorescence in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No.

RetinalGeniX IRB Approved to Conduct Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration

Retrieved on: 
Monday, October 30, 2023
Biomarker, Ophthalmology, Institutional review board, Intravitreal injection, Hematology, AMD, BrightFocus Foundation, MD, Research, Anti-VEGF, OTCQB, JAMA Ophthalmology, News, Disease, University, Personalized medicine, Blood, Safety, Patient, Pharmaceutical industry

The study aims to offer recommendations for enhancing the preselection process and management of ocular injections.

Key Points: 
  • The study aims to offer recommendations for enhancing the preselection process and management of ocular injections.
  • The proposed patient selection process has the potential to reduce the cost and improve the safety and efficacy of patient candidate selection for ocular injections.
  • “RetinalGeniX DNA/GPS has submitted a study with Pearl IRB to perform a clinical review of 390 patients.
  • Jerry Katzman, MD, the CEO of RetinalGeniX, emphasized the importance of limiting ocular anti-VEGF injections into patients’ eyes for those who are good candidates for responsive treatment.

Prevent Blindness Provides Informational Resources to Professionals and the Public for November's Diabetes-related Eye Disease Awareness Month

Retrieved on: 
Wednesday, October 25, 2023
UnitedHealth Group, Social media, Population health, US, American Diabetes Association, Diabetic retinopathy, Prevalence, Health, Mental, Disease, Risk, Eye, Public, Paratriathlon, Potential, Retina, Parent, Mental health, MHS, Yale School of Medicine, Organization, Prediabetes, National Eye Institute, CDC, Centers for Disease Control and Prevention, Vision, VSP Vision Care, Research, JAMA Ophthalmology, Visual impairment, Microsoft PowerPoint, Research to Prevent Blindness, MBA, Database, Johns Hopkins School of Medicine, Associate, Pharmaceutical industry, Ophthalmology, Regeneron Pharmaceuticals, MD, Diabetes

CHICAGO, Oct. 25, 2023 /PRNewswire-PRWeb/ -- A recent study, "Prevalence of Diabetic Retinopathy in the US in 2021," estimated that more than 26 percent of people with diabetes had diabetic retinopathy. Diabetic retinopathy, the most common form of diabetes-related eye disease, is the leading cause of blindness in adults age 20–74, according to the National Eye Institute.

Key Points: 
  • Diabetic retinopathy, the most common form of diabetes-related eye disease, is the leading cause of blindness in adults age 20–74, according to the National Eye Institute .
  • The longer a person has diabetes, the greater the risk for diabetes-related eye disease.
  • Prevent Blindness , the nation's leading nonprofit eye health and safety organization, has declared November as Diabetes-related Eye Disease Awareness Month, providing the public with a variety of helpful tools to prevent unnecessary vision loss from diabetes.
  • Vision Integration Library - The Center for Vision and Population Health at Prevent Blindness offers the free "Vision Integration Library: Vision and Eye Health Resource Center at Prevent Blindness."

Kubota Vision Announces Collaborative Research Agreement with China Medical University Hsinchu Hospital

Retrieved on: 
Thursday, September 7, 2023
Hospitals, Health, Science, Research, Optical, Near-sightedness, Arm, Safety, Atropine, Doctor of Philosophy, JAMA Ophthalmology, MD, Patient, Treatment, Clinical study design, Pharmaceutical industry, Medicinal plants, Ophthalmology

Kubota Vision Inc. (“Kubota Vision” or the “Company”), a clinical-stage specialty ophthalmology company and a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the execution of a collaborative research agreement between Kubota Vision and China Medical University Hsinchu Hospital, Department of Ophthalmology, for a study using Kubota Glass in Taiwan, led by Dr. Ying-Shan Chen.

Key Points: 
  • Kubota Vision Inc. (“Kubota Vision” or the “Company”), a clinical-stage specialty ophthalmology company and a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the execution of a collaborative research agreement between Kubota Vision and China Medical University Hsinchu Hospital, Department of Ophthalmology, for a study using Kubota Glass in Taiwan, led by Dr. Ying-Shan Chen.
  • Dr. Chen is a globally renowned leader in myopia research and treatment, serving as the chief of Ophthalmology at China Medical University Hsinchu Hospital.
  • Dr. Chen stated, “Progressive myopia poses a heavy burden to individuals and society as a whole.
  • Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial.

Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq

Retrieved on: 
Tuesday, July 18, 2023
Biotechnology, Pharmaceutical, Optical, Medical Supplies, Surgery, Health, FDA, Clinical Trials, DED, Harald von Boehmer, University, Therapy, Patient satisfaction, Efficacy, Sheppard, Eye, Telecanthus, Pharmacokinetics, ASCRS, Multimedia, Inflammation, Cornea, Random phase approximation, Stinger, Ophthalmology, Acquisition, Oil, Patient, BID, Political moderate, University of Pikeville, Ciclosporin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, News, Treatment, Food, JAMA Ophthalmology, Pharmaceutical industry, Safety

“VEVYE, which is expected to be available soon, is a unique cyclosporine formulation indicated for treatment of the signs and symptoms of DED.

Key Points: 
  • “VEVYE, which is expected to be available soon, is a unique cyclosporine formulation indicated for treatment of the signs and symptoms of DED.
  • In this study, VEVYE was shown to be safe, and no systemic exposure of cyclosporin was observed after ocular administration.
  • Schirmer’s tear test responses of ≥10 mm increase was statistically significantly higher in the VEVYE compared vehicle at Day 29.
  • Wirta DL, Krösser S, Long -Term Safety and Efficacy of a Water-Free Cyclosporine Ophthalmic Solution for the Treatment of Dry‑Eye Disease: ESSENCE-2-OLE study.

RetinalGeniX Technologies, Inc. Nears Completion of Institutional Review Board for Research on DNA/GPS Program

Retrieved on: 
Monday, June 26, 2023
National Center for Advancing Translational Sciences, Institutional review board, Macular degeneration, AMD, University, OTCQB, BrightFocus Foundation, National Center for Biotechnology Information, Research, Paratriathlon, Biomarker, Ophthalmology, Patient, IRB, Hematology, Disease, JAMA Ophthalmology, Pharmaceutical industry

PETALUMA, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today previewed the completion of an Institutional Review Board (“IRB”) for research on its DNA/GPS program.

Key Points: 
  • PETALUMA, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today previewed the completion of an Institutional Review Board (“IRB”) for research on its DNA/GPS program.
  • "We are near completion of an IRB for research on its DNA/GPS program.
  • The study will follow global standards for ophthalmology research to ensure that the resulting biomarkers can be universally applied.
  • The goal of the study is to personalize medical evaluations for patients receiving treatment for macular degeneration.

Study Finds Significantly More Adults Living with Diabetic Retinopathy in the United States than Previously Estimated

Retrieved on: 
Friday, June 16, 2023
Retina, Microsoft PowerPoint, University, Prevalence, Diabetes, Education, Visual impairment, Diabetic retinopathy, Centers for Disease Control and Prevention, Public, Policy, Eye, DR, Brain, Cell, Social media, Person, CDC, Vision, Ophthalmology, Institute for Health Metrics and Evaluation, Public health, NORC, Patient, Bleeding, Risk, University of Washington Department of Global Health, NORC at the University of Chicago, Mortality, Paratriathlon, MPH, White, IHME, Safety, Pharmaceutical industry, Medical device, Nursing, Soft drink, Toy, Dietary supplement, Doctor of Philosophy, JAMA Ophthalmology

CHICAGO, June 16, 2023 /PRNewswire-PRWeb/ --  A new study published today in JAMA Ophthalmology, "Prevalence of Diabetic Retinopathy in the US in 2021," found that in 2021, an estimated 9.6 million people in the United States (26.4 percent of those with diabetes) had diabetic retinopathy (DR), and 1.84 million people (5.1 percent of those with diabetes) had vision-threatening diabetic retinopathy (VTDR). The number of people aged 40 years and older living with diabetes-related eye disease more than doubled since prevalence was last estimated in 2004. VTDR has also almost doubled since last estimated in 2004.

Key Points: 
  • New study finds that nearly 10 million people in the US with diabetes have diabetic retinopathy.
  • The number of people aged 40 years and older living with diabetes-related eye disease more than doubled since prevalence was last estimated in 2004.
  • The study is the first of its kind to estimate the prevalence of DR and VTDR in people younger than 40 years.
  • For more information on the "The Prevalence of Diabetic Retinopathy in the United States In 2021" study or the VEHSS, visit https://www.cdc.gov/visionhealth/vehss/ .

Adverum Biotechnologies Presents Nonclinical Data at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vec

Retrieved on: 
Sunday, April 23, 2023
Consensus, McKibbin, ARVO, Adverum Biotechnologies, NOAEL, AMD, Eye, LUNA, Inflammation, Publication, George Loewenstein, Burak Eldem, Administration, Incidence, JAMA Ophthalmology, Patient, Vance DeGeneres, Association for Research in Vision and Ophthalmology, Research, No-observed-adverse-effect level, Visual acuity, New Orleans, Pharmaceutical industry, Vaccine, Publishing, Ophthalmology, NHP

REDWOOD CITY, Calif., April 23, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced nonclinical data supporting the two doses of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) being evaluated in the Phase 2 LUNA trial and the potential for staggered, bilateral administration in the treatment of wet AMD. The data were featured in an oral presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting in New Orleans, Louisiana.

Key Points: 
  • The data were featured in an oral presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting in New Orleans, Louisiana.
  • Administration of a single intravitreal dose of Ixo-vec in the second eye resulted in peak aflibercept levels that are within the targeted therapeutic range.
  • Despite elevated systemic humoral response after first eye injection, second eye total antibodies were undetectable prior to injection of Ixo-vec dose in the second eye.
  • The presentation will be made available on the Publications page of the Adverum website.

Real-World Experience Shows TEPEZZA® (teprotumumab-trbw) Was Effective in Treating People With Dysthyroid Optic Neuropathy (DON)

Retrieved on: 
Sunday, March 12, 2023
Biotechnology, FDA, Health, Neurology, Other Health, Radiology, Pharmaceutical, Surgery, Optical, Other Science, Research, General Health, Science, Clinical Trials, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, University, Ophthalmology, Hospital of the University of Pennsylvania, Diplopia, JAMA Ophthalmology, Risk, Exophthalmos, Graves' ophthalmopathy, DON, Radiation, Hyperglycemia, Quality of life, Patient, Nausea, CAS, Hospital, Medicine, TED, Food, Spasm, Physician, Fatigue, Literature, Visual acuity, Paratriathlon, Pharmaceutical industry, Medical imaging, Dysgeusia

Horizon Therapeutics plc (Nasdaq: HZNP) today announced results of an analysis of real-world treatment with TEPEZZA in Thyroid Eye Disease (TED) patients with DON, the majority of whom had not previously responded to other treatments.

Key Points: 
  • Horizon Therapeutics plc (Nasdaq: HZNP) today announced results of an analysis of real-world treatment with TEPEZZA in Thyroid Eye Disease (TED) patients with DON, the majority of whom had not previously responded to other treatments.
  • During this period, 24 patients were identified from literature and the author’s clinical experience with most (22 out of 24) receiving treatment with oral or intravenous steroids, surgery and/or radiation prior to TEPEZZA.
  • Reported adverse events were consistent with TEPEZZA clinical trials and included fatigue, dysgeusia, hearing issues, nausea, hyperglycemia and muscle spasms.
  • “This research underscores our ongoing commitment to ensuring patients receive appropriate care that can result in improved clinical outcomes.”

AXIM® Biotechnologies Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test; Files Provisional Patent

Retrieved on: 
Tuesday, December 13, 2022
Allergic conjunctivitis, Eye, DED, Physician, Diagnosis, Annual report, JAMA Ophthalmology, Inflammation, Catalog, SAN, Duane syndrome, Health, Immunoglobulin E, FDA, Patent, American Academy of Ophthalmology, Drug Quality and Security Act, American Academy, Research, Biomarker, American Journal, Patient, Pharmaceutical industry, Biotechnology, Ophthalmology, Lactoferrin

The first-of-its-kind test is designed to be administered at the point-of-care and will measure both IgE and MMP-9 levels in patients, rendering results in 10 minutes.

Key Points: 
  • The first-of-its-kind test is designed to be administered at the point-of-care and will measure both IgE and MMP-9 levels in patients, rendering results in 10 minutes.
  • This sample size significantly reduces patient discomfort in tear collection, where only one sample is needed to measure levels of both biomarkers.
  • AXIM’s diagnostic solutions seek to address this severely unmet clinical need and the addition of this test to AXIM’s portfolio only further positions the company as a leader in innovative ophthalmological diagnostic solutions.
  • The Company owns two of the only five FDA Cleared Diagnostic tests for Dye Eye Disease.